BIOQUAL, Inc.
BIOQ
$56.00
-$1.50-2.61%
| 11/30/2024 | 08/31/2024 | 11/30/2023 | 11/30/2023 | 05/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 11.40M | 11.77M | 15.87M | 15.87M | 16.07M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.40M | 11.77M | 15.87M | 15.87M | 16.07M |
| Cost of Revenue | 11.51M | 11.33M | 13.33M | 13.33M | 11.13M |
| Gross Profit | -113.60K | 437.30K | 2.54M | 2.54M | 4.94M |
| SG&A Expenses | 1.71M | 1.57M | 1.97M | 1.97M | 6.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.22M | 12.90M | 15.31M | 15.31M | 17.13M |
| Operating Income | -1.82M | -1.13M | 562.40K | 562.40K | -1.06M |
| Income Before Tax | -1.67M | -931.80K | 668.60K | 668.60K | -1.04M |
| Income Tax Expenses | -460.20K | -256.50K | 183.90K | 183.90K | -338.90K |
| Earnings from Continuing Operations | -1.21M | -675.30K | 484.70K | 484.70K | -702.10K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.21M | -675.30K | 484.70K | 484.70K | -702.10K |
| EBIT | -1.82M | -1.13M | 562.40K | 562.40K | -1.06M |
| EBITDA | -1.23M | -512.10K | 1.20M | 1.20M | -432.70K |
| EPS Basic | -1.36 | -0.76 | 0.54 | 0.54 | -0.79 |
| Normalized Basic EPS | -1.17 | -0.65 | 0.47 | 0.47 | -0.73 |
| EPS Diluted | -1.36 | -0.76 | 0.54 | 0.54 | -0.79 |
| Normalized Diluted EPS | -1.17 | -0.65 | 0.47 | 0.47 | -0.73 |
| Average Basic Shares Outstanding | 894.40K | 894.40K | 894.40K | 894.40K | 894.40K |
| Average Diluted Shares Outstanding | 894.40K | 894.40K | 894.40K | 894.40K | 894.40K |
| Dividend Per Share | -- | -- | -- | -- | 0.50 |
| Payout Ratio | -36.89% | -- | 92.27% | 92.27% | 0.00% |
